

Coronavirus (COVID19) Statement

Sydney, Australia, Tuesday, 17 March 2020: Next Science Limited (ASX:NXS), an Australian medical technology company whose primary commercial business, at this stage in the growth cycle, is in the United States health market, provides the following update.

Sales

As a result of the impact of the COVID19 outbreak in the United States, we are seeing some disruption to activities including reduced hospital visits by Next Science's distribution agents, postponement of medical congresses and a reduction in the number of elective procedures. We continue to service existing customers and distribution partners, although new account growth with hospitals is being temporarily affected.

As a result, sales growth has been impacted, and this is likely to continue until access to customers is restored.

It is too early to reasonably anticipate sales in Q2. While we expect access to customers to facilitate the marketing and sales cycle to be reinstated in full over time, future sales growth in the US will partly depend on the duration of the State of Emergency status.

COVID19

Next Science's core purpose is to eradicate biofilm protected bacteria and therefore, prevent and treat infection.

Next Science has a number of products in market, with others expected to be launched this calendar year following FDA approval, that are effective in the removal of COVID 19-like viruses.

Next Science also expects to benefit from the marked increase in focus throughout the world on infection prevention. This increase in awareness should lead over time to further demand for the Company's proprietary infection control and treatment products.

Our current products are all effective in the removal of COVID19-like viruses:

Bactisure Surgical Lavage	– removes bacteria and viruses in the surgical field
BlastX Chronic Wound Gel	– removes bacteria and viruses in infected wounds
SurgX Sterile Wound Gel	– prevents infections in surgical procedures from bacteria and viruses

We are also continuing to make progress in gaining regulatory approval in the United States for two new products to further address infection. We anticipate commercial launch of these new products in the US market in H2 2020:

Surface Disinfectant	– removes biofilm, bacteria and viruses (including COVID19-like viruses) from hard surfaces
XPerience surgical rinse	– removes biofilms, bacteria and viruses in the surgical field.

Safety & 5 New Product Launches in 2020

Our priority is to ensure the safety of our staff and other stakeholders. An infection management policy has been put in place at Next Science's Research & Development centre in Jacksonville to ensure staff safety and business continuity. Work is continuing on product development and regulatory testing. Next Science does not anticipate changes to the timetable to release five new products to market in 2020

Approved by the Board.

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: www.nextscience.com.